Your email has been successfully added to our mailing list.

×
0.195652173913044 0.195652173913044 0.195652173913044 0.195652173913044 -0.0217391304347826 0.0434782608695653 0.0434782608695653 0.0869565217391305
Stock impact report

Mateon Therapeutics Team Publishes Three New Peer-Reviewed Oncology Articles Outlining the Clinical Impact Potential of Its First-In-Class Anti-TGF-Beta RNA Therapeutic OT101/Trabedersen

Mateon Therapeutics (MATN)  More Company Research Source: GlobeNewswire
Last mateon therapeutics earnings: 11/19 05:25 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.mateon.com
PDF AGOURA HILLS, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN, “Mateon”) dedicated to the development of innovative treatments for cancer, announced today the publication of two peer-reviewed expert editorials authored by Fatih Uckun MD PhD, the Chief Medical Officer for Mateon, and Vuong Trieu, PhD, the Chief Executive Officer and President for Mateon, at Oncotelic in the oncology journals Cancer Clinics Journal and Annals of Hematology and Oncology Research. Also published was a peer-reviewed research article in the prestigious oncology journal Cancers. The editorial titled “Monotherapy of High-Grade Gliomas with a TGF-beta2 Targeting RNA Therapeutic" provides an overview regarding the development status, mechanism of action, and clinical potential of Mateon’s first-in-class RNA therapeutic OT101 for the treatment of the most aggressive brain tumors in adults. Citation Reference:  Uckun FM, [Read more]
Impact snapshot Event time: MATN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
MATN alerts
from News Quantified
Opt-in for
MATN alerts

from News Quantified
Opt-in for
MATN alerts

from News Quantified